#1 Clinical Trials Search in Europe

Eo2318

This article explores the use of EO4010, a groundbreaking cancer vaccine therapy, in clinical trials for patients with previously treated metastatic colorectal cancer. The study aims to evaluate the safety and effectiveness of EO4010 when combined with other cancer treatments, offering new hope for patients who have already undergone standard therapies.

Table of Contents

What is EO2318?

EO2318 is a component of a novel cancer vaccine therapy called EO4010[1]. It is being developed as a potential treatment for patients with advanced colorectal cancer. EO2318 is classified as a microbial-derived peptide therapeutic vaccine, which means it is made from small protein fragments derived from microorganisms that can stimulate the immune system to fight cancer cells[1].

Medical Conditions Treated

EO2318, as part of the EO4010 vaccine, is being studied for the treatment of metastatic colorectal cancer[1]. Specifically, it is intended for patients with:

  • Unresectable (cannot be removed by surgery) colorectal cancer
  • Locally advanced or metastatic colorectal cancer (cancer that has spread to other parts of the body)
  • Cancer that has been previously treated with other therapies

How EO2318 Works

EO2318 is part of a cancer vaccine that aims to stimulate the body’s immune system to recognize and attack cancer cells. It works in the following ways:

  1. Immune System Activation: The vaccine helps to activate T cells, which are important immune cells that can recognize and destroy cancer cells[1].
  2. Targeting Tumor Antigens: EO2318 is designed to help T cells recognize specific proteins (called tumor-associated antigens or TAAs) that are found on colorectal cancer cells[1].
  3. Combination Therapy: In the clinical trial, EO2318 (as part of EO4010) is being tested in combination with other cancer drugs like nivolumab (an immune checkpoint inhibitor) and bevacizumab (a drug that blocks blood vessel growth in tumors)[1]. This combination approach may enhance the overall effectiveness of the treatment.

Clinical Trial Details

EO2318 is currently being studied in a clinical trial called the “AUDREY” study[1]. Here are some key details about the trial:

  • Trial Phase: This is a Phase 1/2 trial, which means it is testing both the safety and potential effectiveness of the treatment[1].
  • Study Design: The trial is divided into different cohorts (groups) to test various combinations of EO4010 (which includes EO2318) with other cancer drugs[1].
  • Treatment Schedule: Patients will receive regular treatments and undergo various tests and procedures as outlined in the study protocol[1].
  • Follow-up: After treatment, patients will have follow-up visits to monitor their health and the effects of the treatment[1].

Eligibility Criteria

To participate in the clinical trial for EO2318 (as part of EO4010), patients must meet certain criteria. Some key eligibility factors include:

  • Being 18 years of age or older[1]
  • Having HLA-A2 positive colorectal cancer (a specific genetic marker)[1]
  • Having advanced colorectal cancer that has been previously treated or is not suitable for standard treatments[1]
  • Having a good overall health status (ECOG performance status of 0 to 1)[1]
There are also several factors that may exclude a patient from participating, such as certain previous treatments or medical conditions. A healthcare provider can provide more detailed information about eligibility[1].

Potential Benefits

While the effectiveness of EO2318 (as part of EO4010) is still being studied, the clinical trial aims to evaluate several potential benefits:

  • Tumor Response: The study will measure if the treatment can shrink tumors or stop them from growing[1].
  • Survival: Researchers will assess if the treatment can help patients live longer without their cancer progressing (progression-free survival) and overall survival[1].
  • Immune Response: The trial will evaluate if the treatment can stimulate the immune system to recognize and attack cancer cells[1].
It’s important to note that as this is an experimental treatment, its benefits are not yet proven and may vary from patient to patient.

Safety and Side Effects

A primary goal of the clinical trial is to evaluate the safety and tolerability of EO2318 (as part of EO4010) when used alone or in combination with other cancer drugs[1]. The researchers will closely monitor patients for any side effects or adverse reactions throughout the study. Common side effects of cancer vaccines and immunotherapies may include:

  • Fatigue
  • Fever
  • Injection site reactions
  • Flu-like symptoms
However, the specific side effects of EO2318 are still being studied. Patients in the trial will be carefully monitored and should report any unusual symptoms to their healthcare team[1].

Aspect Details
Study Type Phase 1/2 clinical trial
Main Treatment EO4010 (novel cancer vaccine therapy)
Combination Therapies Nivolumab and/or Bevacizumab
Target Condition Previously treated metastatic colorectal carcinoma
Primary Objective Evaluate safety and tolerability of EO4010 combinations
Secondary Objectives Assess immunogenicity, tumor response, and survival outcomes
Key Eligibility Criteria HLA-A2 positive, advanced colorectal cancer, previous treatment history
Study Design Multiple cohorts evaluating different treatment combinations
Treatment Duration Expected to be completed by week 43
Follow-up Safety visits at 30 and 100 days post-treatment, ongoing follow-up every 8 weeks

FAQ

  • What is EO4010 and how does it work? EO4010 is a novel microbial-derived peptide therapeutic vaccine designed to stimulate the immune system to fight cancer cells. It works by targeting specific proteins found on colorectal cancer cells, potentially enhancing the body's natural defense mechanisms against the disease.
  • Who is eligible for this clinical trial? The trial is open to HLA-A2 positive patients with advanced non-resectable colorectal adenocarcinoma who have been previously treated with standard therapies or are not considered candidates for such treatments. Patients must be 18 years or older and have an ECOG performance status of 0 to 1.
  • What other treatments are being used in combination with EO4010? The trial is investigating EO4010 in combination with nivolumab (an immune checkpoint inhibitor) and/or bevacizumab (an anti-angiogenic agent). These combinations aim to enhance the overall effectiveness of the treatment against metastatic colorectal cancer.
  • What are the main objectives of this clinical trial? The primary objective is to evaluate the safety and tolerability of EO4010 in combination with nivolumab and/or bevacizumab. Secondary objectives include assessing the immune response, tumor response rates, and survival outcomes in patients receiving the treatment.
  • How long does the treatment phase of the trial last? The treatment phase is expected to be completed by week 43. Patients will receive regularly scheduled visits to receive the study treatment and undergo various procedures as described in the protocol. The treatment may continue as long as the patient benefits from it, unless the disease worsens or other factors lead to discontinuation.

Ongoing Clinical Trials on Eo2318

  • Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Spain

Glossary

  • Metastatic colorectal cancer: Cancer that has spread from the colon or rectum to other parts of the body.
  • EO4010: A novel microbial-derived peptide therapeutic vaccine being studied for the treatment of metastatic colorectal cancer.
  • Nivolumab: An immune checkpoint inhibitor drug that helps the immune system fight cancer cells.
  • Bevacizumab: An anti-angiogenic agent that works by blocking the growth of new blood vessels that feed tumors.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) that is important for the immune system's ability to recognize and respond to foreign substances or cancer cells.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • T cells: A type of white blood cell that plays a central role in the immune response against cancer.
  • Tumor associated antigens (TAAs): Proteins found on cancer cells that can be recognized by the immune system.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease control rate (DCR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-eo4010-vaccine-with-nivolumab-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer-who-have-already-received-treatment/